research
A Liver Treatment Starts With the Gut Barrier
Michigan Medicine says DT-109 reversed severe fatty-liver disease in animal models by repairing intestinal defenses and limiting toxin exposure.
Summary
Michigan Medicine says DT-109 reversed severe fatty-liver disease in animal models by repairing intestinal defenses and limiting toxin exposure.
Michigan Medicine researchers tested the experimental compound DT-109 in animal models of metabolic dysfunction-associated steatohepatitis. The treatment restored gut-barrier function and reduced the passage of damaging microbial products into circulation, while the animals showed reversal of severe disease markers. The work remains preclinical, but it supports treating MASH as a connected gut-liver system instead of a single-organ problem.
Why it matters
Michigan Medicine says DT-109 reversed severe fatty-liver disease in animal models by repairing intestinal defenses and limiting toxin exposure.
Limits and context
- The work remains preclinical, but it supports treating MASH as a connected gut-liver system instead of a single-organ problem.
Key claims
Michigan Medicine says DT-109 reversed severe fatty-liver disease in animal models by repairing intestinal defenses and limiting toxin exposure.
Qualification: The work remains preclinical, but it supports treating MASH as a connected gut-liver system instead of a single-organ problem.
Evidence: source-2026-07-12-006
Sources
- ScienceDaily from Michigan Medicinewww.sciencedaily.com · secondary reporting
Corrections
No corrections have been recorded for this story.